Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

The National Institutes of Health (NIH) is seeking applications for the Blueprint Neurotherapeutics Network (BPN) to support biologic-based therapeutic discovery and development for disorders of the nervous system. The program aims to provide funding for preclinical discovery and development of potential therapeutic biotechnology products and biologics. Applicants will have the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. The BPN will support a wide range of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, cell therapies, and other emerging therapeutic modalities. • The program will support biologic-based therapeutic discovery and development for disorders of the nervous system. • Applicants will have the opportunity to collaborate with NIH-funded consultants and CROs. • The BPN will support a wide range of biotherapeutic modalities. • The program aims to provide funding for preclinical discovery and development of potential therapeutic biotechnology products and biologics. • The NIH will utilize the U44 activity code for this funding opportunity. • The expected application due date is January 27, 2025, and the expected award date is December 1, 2025.